Cryptococcus is a genus of encapsulated yeast responsible for one of the deadliest fungal infections on the planet, killing an estimated 112,000 people each year and accounting for roughly one in five AIDS-related deaths worldwide. Two species cause the overwhelming majority of disease: Cryptococcus neoformans, which overwhelmingly strikes people with weakened immune systems, and Cryptococcus gattii, which can also sicken otherwise healthy individuals. Despite living quietly in soil and bird droppings across every continent, these organisms carry an unusual arsenal of survival tools that let them thrive inside the human body and, with alarming frequency, invade the brain.
Where Cryptococcus Lives
The two main disease-causing species occupy somewhat different environmental niches. C. neoformans is recovered primarily from bird droppings, especially pigeon excrement, while the C. gattii species complex is recovered mainly from trees, particularly eucalyptus species. In one Colombian sampling study, roughly a quarter of pigeon-feces samples tested positive for C. neoformans, whereas none of the eucalyptus samples in the same city yielded the organism. Olive-tree samples from the same region did yield a small number of C. gattii-related isolates, underscoring that both species can turn up in unexpected places.
Pigeon roosts in urban areas are a consistent source. Environmental sampling on the Caribbean island of Bonaire recovered C. neoformans from old pigeon droppings, constituting the first documented environmental occurrence of the pathogen in the Dutch Caribbean. These findings matter because the yeast can persist in dried bird excrement for years. Pigeons themselves do not get sick; their body temperature is too high for the fungus to cause disease, so they serve as amplifiers, spreading contaminated droppings across cities.
C. gattii drew public attention when it began causing infections in the Pacific Northwest of the United States and in western Canada, far from the tropical and subtropical zones where it had traditionally been found. The Pacific Northwest outbreak affected both immunocompromised and immunocompetent people, causing serious illness and death in individuals with no known risk factors.
How People Get Infected
Infection starts in the lungs. People breathe in the fungal particles, which are thought to be either small dried yeast cells or spores produced during sexual reproduction. Both forms are tiny enough to reach the deepest air sacs in the lungs. Once there, the particles encounter alveolar macrophages, the immune cells responsible for cleaning up inhaled debris. How those early encounters play out determines whether the infection is contained or progresses.
Research into the spore-host interaction has reshaped the understanding of early cryptococcosis. Spores appear to interact with macrophages differently than mature yeast cells do, and the outcome of that initial confrontation can set the stage for lifelong latent infection or, in vulnerable people, rapid disease.
The Capsule, Melanin, and Titan Cells
Cryptococcus carries a toolkit of features that help it survive inside the body. Three stand out: its polysaccharide capsule, melanin pigment, and the ability to form enormously enlarged “titan cells.”
The capsule is the first line of defense. It is a thick shell of sugar molecules surrounding the yeast cell, and it directly interferes with the immune system’s ability to engulf and kill the fungus. One key trick involves complement, a set of blood proteins that normally tag invaders for destruction. In strains with large capsules, complement proteins get buried deep inside the capsule rather than sitting on the outer surface, making them invisible to the immune cells that would otherwise latch on and swallow the yeast. The result is that larger capsules reduce the effectiveness of complement-driven killing. Structural features of the capsule also reduce how much complement and antibody bind to the cell surface in the first place, increasing virulence in animal models.
Melanin, the same class of pigment that colors human skin, provides a second layer of protection. Cryptococcus produces melanin using an enzyme called laccase, and this pigment shields the fungus from oxidative damage, extreme temperatures, and even ionizing radiation. Inside the body, immune cells attempt to kill the fungus by bombarding it with reactive oxygen molecules. Melanin scavenges those molecules, blunting the attack. Environmental conditions like pH and temperature influence how much melanin the fungus produces, and melanin-producing cells are better at surviving hydrogen peroxide exposure, the kind of chemical assault macrophages rely on.
Titan cells are a more recently appreciated phenomenon. Inside the lungs, a subset of Cryptococcus cells balloon to enormous sizes, reaching 50 to 100 micrometers in diameter. For context, a normal yeast cell is only about 5 to 10 micrometers across, so titan cells are physically too large for most immune cells to swallow. Experiments using mutant strains that cannot form titan cells showed that those strains had weaker infections, lower fungal counts, and less spread through the body than normal strains. Titan cells also skewed the immune response in the lungs, increasing eosinophil accumulation while decreasing phagocytosis. Researchers have been able to induce titan cell formation in the lab by mimicking the conditions of the lung environment, confirming that it is a regulated response to host conditions rather than a random event.
Reaching the Brain
The most feared complication of cryptococcal infection is meningitis, an infection of the membranes surrounding the brain and spinal cord. To get there, the fungus must cross the blood-brain barrier, one of the tightest biological boundaries in the body. Cryptococcus manages this through at least three routes. It can pass directly through the cells lining brain blood vessels, a process called transcellular traversal. It can slip between those cells by loosening the junctions that hold them together, the paracellular pathway. And it can hitch a ride inside macrophages that cross the barrier as part of normal immune surveillance, a strategy sometimes called the Trojan horse mechanism.
Once inside the brain, the consequences are severe. The fungus accumulates in the subarachnoid space, the fluid-filled region surrounding the brain, and clogs the structures responsible for draining cerebrospinal fluid. This blockage leads to elevated intracranial pressure, which drives the headaches, confusion, vision changes, and altered consciousness that characterize cryptococcal meningitis. Postmortem studies show that organisms and their shed capsular polysaccharide concentrate at the sites where cerebrospinal fluid would normally drain, physically obstructing outflow. Draining fluid through lumbar punctures often provides rapid but temporary relief, with pressure building back up as the fungal burden persists.
The Immune Paradox
A healthy immune system generally keeps Cryptococcus in check after the initial lung exposure. CD4+ T cells, the same population destroyed by HIV, are critical for organizing the antifungal response. That is why advanced HIV infection is by far the biggest risk factor for cryptococcal disease. But the relationship between immunity and outcome is not as straightforward as “more immune response equals better.”
In a striking mouse study of cryptococcal meningitis, CD4+ T cells successfully drove a hundredfold reduction in fungal burden in the brain, yet more than half the animals still died. Depleting CD4+ cells prevented fungal clearance but also prevented the clinical symptoms and death, suggesting that the immune response itself was causing fatal brain damage. This immunopathology, where the cure is as dangerous as the disease, is one reason that treating cryptococcal meningitis is so complicated. Physicians must fight the infection while being mindful that immune activation in a confined space like the skull can be lethal on its own.
Latent Infection and Reactivation
Not everyone who breathes in Cryptococcus gets sick right away. In many people, the initial lung infection is contained and the fungus enters a dormant state. Yeast cells survive inside granulomas, organized clusters of immune cells that wall off the pathogen, and inside macrophages themselves. Disease can then result from reactivation of that latent infection years or decades later, if the immune system weakens.
Animal studies have mapped the phases of granuloma formation during latency. In one model, mice progressed through three distinct immune stages: an early phase dominated by eosinophils and certain inflammatory signals during which the fungus still proliferated; a middle phase characterized by the formation of giant cells and expanding granulomas; and a late phase in which T cells surged and the fungal burden finally dropped. Understanding these phases matters because identifying which immune responses are beneficial versus harmful could help guide future treatments or vaccines.
The Global Toll
Cryptococcal meningitis is one of the leading killers of people living with HIV. A 2022 modeling analysis estimated roughly 152,000 cases and 112,000 deaths annually, accounting for about 19% of all AIDS-related mortality worldwide. Earlier estimates from 2014 data put the figures even higher, at about 223,000 incident cases and 181,000 deaths per year, with sub-Saharan Africa bearing approximately three-quarters of the global burden. The decline between estimates reflects expanded access to antiretroviral therapy, though the toll remains staggering. For comparison, these death numbers rival those of tuberculosis in HIV-positive populations.
Among people with very low CD4 counts (below 100 cells per microliter), roughly 6% test positive for cryptococcal antigen in their blood even before they develop symptoms. Identifying these individuals before they progress to meningitis is one of the most promising strategies for reducing deaths.
Diagnosis
The introduction of the cryptococcal antigen lateral flow assay, or CrAg LFA, was a turning point in diagnosis. This test works like a home pregnancy test: a dipstick is dipped in blood, cerebrospinal fluid, or urine, and a visible line appears within minutes if the cryptococcal antigen is present. It requires little to no laboratory infrastructure, making it usable in the rural clinics and resource-limited hospitals where most cases occur. In multisite validation studies, the CrAg LFA achieved about 99% sensitivity and 99% specificity for diagnosing cryptococcal meningitis from cerebrospinal fluid, outperforming older methods like latex agglutination and India ink microscopy.
The test has also found an important role in screening. By running the LFA on leftover blood samples from CD4 count testing, clinics can identify HIV-positive patients with subclinical cryptococcal infection before they develop meningitis. Those patients can then receive preemptive antifungal treatment, a strategy that has the potential to prevent thousands of deaths per year in high-burden regions.
Treatment and the Problem of Drug Resistance
The standard treatment for cryptococcal meningitis combines amphotericin B, a powerful but toxic intravenous antifungal, with flucytosine during an initial induction phase, followed by long-term oral fluconazole to prevent relapse. A landmark trial in Africa showed that flucytosine was a superior partner drug to fluconazole during induction: the combination of one week of amphotericin B plus flucytosine yielded the lowest ten-week mortality at about 24%, compared with roughly 45% mortality when fluconazole was used alongside amphotericin B instead. Yet amphotericin B is hard to administer and causes serious side effects, including severe anemia, and flucytosine remains unavailable in many of the countries most affected by the disease.
Fluconazole resistance adds another layer of difficulty. Cryptococcus exhibits a phenomenon called heteroresistance, in which a small fraction of cells within a population can grow at drug concentrations that kill the majority. This property appears to be intrinsic to the species: even strains isolated before fluconazole existed show heteroresistance. When exposed to increasing drug concentrations, resistant subpopulations expand, but they revert to baseline resistance levels when the drug is removed. This on-again, off-again resistance pattern likely contributes to the frequent relapses seen during fluconazole maintenance therapy. At the molecular level, some resistant cells carry an extra copy of an entire chromosome, leading to overproduction of the drug target and the efflux pump that expels the drug from the cell.
Why Cryptococcus Is So Good at Being a Pathogen
One of the more fascinating questions in infectious disease is why an environmental fungus that has no need for a human host is so well equipped to cause lethal disease. The leading explanation is the “accidental pathogen” hypothesis: Cryptococcus evolved its survival traits not to infect mammals but to fend off predatory amoebae in the soil. Amoebae engulf and digest microbes much the way our macrophages do, so traits that help the fungus resist being eaten by amoebae, like the capsule and melanin, also help it resist being killed by immune cells.
Early experiments showed that cryptococcal traits contributing to mammalian virulence also promoted survival inside amoebae, and that incubation with amoebae could enhance the virulence of fungal strains. More recent work has added nuance. Genetic mapping identified a specific gene, BZP4, that influences both amoeba resistance and melanin production. But variation in that gene did not predict how well the fungus survived inside macrophages or how virulent it was in mice. The relationship between environmental predation and human disease is clearly real, but it is more tangled than a simple “train against amoebae, accidentally kill humans” story.
Immune Reconstitution Inflammatory Syndrome
For HIV-positive patients who start antiretroviral therapy after developing cryptococcal meningitis, recovery brings its own danger. As the immune system rebuilds, it can mount an overwhelming inflammatory response against residual fungal antigens still present in the brain. This reaction, called immune reconstitution inflammatory syndrome (IRIS), can worsen neurological symptoms and kill patients even as their HIV is coming under control.
The immunology behind IRIS helps explain why it is so hard to manage. Before antiretroviral therapy, the immune response to Cryptococcus in severely immunosuppressed patients leans toward an ineffective pattern that fails to clear the fungus. When therapy restores immune function, the pendulum swings hard in the opposite direction, producing an exaggerated inflammatory response. The conventional treatment for IRIS is corticosteroids, but evidence suggests steroids in this setting correlate with increased mortality and significant adverse events. Alternative approaches, including drugs that target specific inflammatory pathways, are under investigation. Timing of antiretroviral therapy relative to antifungal treatment is critical: starting HIV drugs too soon after a cryptococcal diagnosis increases the risk of IRIS, which is why current guidelines recommend delaying antiretroviral therapy for several weeks after beginning antifungal induction.
Vaccine Research
There is no approved vaccine against Cryptococcus, but early-stage research is encouraging. One promising approach uses a heat-killed version of a genetically modified C. neoformans strain that accumulates an unusual lipid called sterylglucoside. In mouse experiments, the live version of this mutant was unable to cause disease and protected animals from a subsequent lethal challenge. When researchers tested a heat-killed preparation of the same strain as a therapeutic vaccine, given after infection had already been established, it significantly reduced the fungal burden in the lungs. Depending on the timing of administration, survival rates reached 70% to 100%. Strikingly, this vaccine also prevented reactivation of latent infection in mice whose immune systems were then deliberately suppressed, a scenario that mimics what happens in HIV patients.
These are still animal studies, and no human trials are underway yet. But the fact that even a killed preparation can rescue animals from active infection, and prevent reactivation under immunosuppression, marks an unusual achievement in fungal vaccine development.
Cryptococcus in Animals
Cryptococcal infection is not limited to humans. Cats, dogs, koalas, and a range of wild mammals develop disease, with koalas being especially susceptible to C. gattii in areas where the fungus is endemic. Domestic cats and dogs typically present with nasal masses, skin nodules, or neurological signs, and veterinarians in subtropical and tropical regions regularly diagnose the infection. Wildlife species can serve as disease sentinels, flagging the presence of Cryptococcus in an environment before human cases appear. Tracking infections in animals contributes to the broader “One Health” perspective, recognizing that human, animal, and environmental health are deeply linked when it comes to understanding where the fungus circulates and when conditions favor outbreaks.
Sexual Reproduction and Genetic Diversity
Cryptococcus has a complex and versatile reproductive life. It can mate in the conventional sense, with two cells of opposite mating types fusing, but it can also undergo “unisexual” reproduction, in which cells of the same mating type fuse or a single cell undergoes the sexual cycle alone. Both processes generate spores, the very particles thought to cause infection, and both generate genetic diversity. This matters for disease because sexual reproduction can shuffle virulence traits between strains. In crosses between hypervirulent and less virulent lineages of C. gattii, researchers found that virulence traits could be transmitted to offspring, but the pattern was complex: multiple regions of the nuclear genome, not just one gene, interacted with mitochondrial factors to regulate how dangerous a strain became.
The genes governing mating are clustered in a large mating-type locus that influences not just reproduction but also pathogenesis and population structure. In most clinical populations of C. neoformans, one mating type dominates overwhelmingly, raising questions about how much sexual reproduction actually occurs in nature versus in the laboratory. Yet the genetic diversity observed in clinical and environmental isolates makes it clear that recombination happens often enough to keep shuffling the deck.